Related Experiment Videos
Is cholesterol the major lipoprotein risk factor in coronary heart disease?--a Franco-Scottish overview
1Department of Atherosclerosis and INSERM (Unit 325), Institut Pasteur, Lille, France.
Insights
Lowering plasma lipids, including cholesterol and triglycerides, significantly reduces coronary heart disease (CHD) risk. Triglycerides are increasingly recognized as a key lipoprotein risk factor, especially in younger myocardial infarction patients.
Area of Science:
- Cardiovascular Medicine
- Lipidology
- Atherosclerosis Research
Background:
- Hyperlipidemia's role in coronary heart disease (CHD) has been debated for decades.
- While cholesterol reduction benefits CHD, other lipoproteins may also be significant risk factors.
- Triglycerides are increasingly recognized for their impact on cardiovascular health.
Purpose of the Study:
- To review the evolving understanding of lipid management in coronary heart disease.
- To highlight the significance of triglycerides as a cardiovascular risk factor.
- To discuss the efficacy of lipid-lowering therapies in preventing and managing atherosclerosis.
Main Methods:
- Review of clinical studies and epidemiological data on hyperlipidemia and CHD.
- Analysis of treatment outcomes from trials involving lipid-lowering medications.
- Examination of pathophysiological research into atherosclerosis.
Main Results:
- Cholesterol reduction shows benefits in primary and secondary CHD prevention.
- High triglyceride levels, particularly with hypercholesterolemia, correlate with greater CHD reduction in some treatments.
- Low-density lipoprotein (LDL) reduction is beneficial even with normal total cholesterol post-myocardial infarction.
- Fibrates and HMG-CoA reductase inhibitors can halt or even reverse atheromatous lesion progression.
Conclusions:
- Lipid management is crucial for coronary heart disease prevention and treatment.
- Triglycerides represent a significant, often underestimated, risk factor for CHD.
- Further research into atherosclerosis pathophysiology will refine the use of hypolipidemic agents.
Abstract:
There has been much debate over the past three decades concerning the role of hyperlipidaemia in coronary heart disease (CHD) and the efficacy of reducing plasma lipids levels. Although reduction in plasma cholesterol has been associated with a favourable effect on both primary and secondary CHD, there is a growing feeling that cholesterol may not be the only significant lipoprotein risk factor to be involved. Only relatively recently has the true role of triglycerides become apparent. Studies have indicated that the greatest reduction in CHD with some treatments has been found in those patients in whom high triglyceride levels accompany hypercholesterolaemia. In particular, in younger patients who have suffered a myocardial infarction, hypertriglyceridaemia is more common than hypercholesterolaemia. Nevertheless, recent large studies have shown that reduction of low-density lipoprotein (LDL) is beneficial, even in post-infarction patients with a relatively normal total cholesterol level. Furthermore, studies with fibrates and with HMG Co-A reductase inhibitors have indicated that progression of atheromatous lesions can be halted and in may cases there is evidence of regression. Continuing research on the pathophysiology of atherosclerosis, including the role of macrophages and thrombotic involvement, will further define the role of hypolipidaemics in the prevention and management of coronary heart disease.